PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 15 |
| 2007 | 20 |
| 2008 | 131 |
| 2009 | 150 |
| 2010 | 158 |
| 2011 | 127 |
| 2012 | 103 |
| 2013 | 149 |
| 2014 | 126 |
| 2015 | 104 |
| 2016 | 115 |
| 2017 | 132 |
| 2018 | 116 |
| 2019 | 104 |
| 2020 | 101 |
| 2021 | 137 |
| 2022 | 97 |
| 2023 | 89 |
| 2024 | 90 |
| 2025 | 95 |
| 2026 | 94 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Mol Cancer Ther"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Nanoparticle Co-delivery of Microtubule Inhibitors and Cisplatin Overcomes DNA Repair-Mediated Resistance in Head and Neck Cancer.
- Li X, Palchak L, Wang L, Bhat DS, Salem AK, Sokolsk M, Kabanov AV, Peng A.
- Mol Cancer Ther. Author manuscript. 2026 Sep 23:10.1158/1535-7163.MCT-25-1239. doi: 10.1158/1535-7163.MCT-25-1239. Online ahead of print.
- PMCID: PMC13685908
Li X, et al.Mol Cancer Ther. Author manuscript. 2026.PMCID: PMC13685908 -
Differential Sensitivity to xCT-inhibition by ME1 expression.
- Caldwell KE, Brashears CB, Mehta S, Whelchel JP, Barr D, Roggin JP, Spitzer D, Van Tine BA, Hawkins WG.
- Mol Cancer Ther. Author manuscript. 2026 Sep 22:10.1158/1535-7163.MCT-25-0299. doi: 10.1158/1535-7163.MCT-25-0299. Online ahead of print.
- PMCID: PMC13679071
Caldwell KE, et al.Mol Cancer Ther. Author manuscript. 2026.PMCID: PMC13679071 -
CerS2 Is a Druggable Target in Triple-Negative Breast Cancer.
- Alatawi H, Nair HH, Ai L, Mahmud I, Gour A, Singh A, Baek D, Yan B, Maharjan CK, Zhang W, Law BK, Zajac-Kaye M, Vulpe C, Guryanova OA, Sharma AK, Garrett TJ, Sharma A, Heldermon CD, Hong S, Narayan S.
- Mol Cancer Ther. Author manuscript. 2026 Jul 2;25(7):1095-1110. doi: 10.1158/1535-7163.MCT-25-1159.
- PMCID: PMC13678703
Alatawi H, et al.Mol Cancer Ther. Author manuscript. 2026.PMCID: PMC13678703 -
Targeting pancreatic cancer with adenoviral vectors equipped with transgenes.
- Roach BL, Sato-Dahlman M, Jacobsen K, Gates T, Shanley R, Stromnes IM, Yamamoto M.
- Mol Cancer Ther. Author manuscript. 2026 Sep 24:10.1158/1535-7163.MCT-25-1231. doi: 10.1158/1535-7163.MCT-25-1231. Online ahead of print.
- PMCID: PMC13671789
Roach BL, et al.Mol Cancer Ther. Author manuscript. 2026.PMCID: PMC13671789 -
An Integrin β6-Targeted Antibody-Drug Conjugate Optimized for Intravesical Delivery to Treat Non-Muscle-Invasive Bladder Cancer.
- Carosino CM, Olson DJ, Mazahreh RC, Ortiz DJ, Duniho S, Moskovitz E, Gray M, Hein RF, Garcia NH, Ardalani H, Farr L, Yan T, Burcher M, Mikell I, Levengood MR, Sandall S, Dekker JD.
- Mol Cancer Ther. 2026 Oct 2;25(10):1716-1730. doi: 10.1158/1535-7163.MCT-26-0077.
- PMCID: PMC13631498
Carosino CM, et al.Mol Cancer Ther. 2026.PMCID: PMC13631498 -
Targeting the Chromatin-Modifying Enzyme, KDM5C, Enhances AKT Inhibition Response in ER+ Breast Cancer.
- Cutano V, Dunn S, Park-Chouinard S, Wigmore EM, Wu Q, Montava Garriga L, Hopcroft L, Esopi D, Chirichella M, Liu S, Eberlein C, Tang M, Lee HJ, Zhang W, Callahan M, Nuttall BRB, Barrell D, Gurran T, Hillis J, Spruce A, Elgendy R, Bradley J, Kim C, Talbot S, Dai L, Rosenberg LH, Ros S, Liu H, Aryal N, Mettetal JT, Chan HM, McDermott U, Barry ST; Functional Genomics Centre.
- Mol Cancer Ther. 2026 Oct 2;25(10):1633-1649. doi: 10.1158/1535-7163.MCT-25-1006.
- PMCID: PMC13631501
Cutano V, et al.Mol Cancer Ther. 2026.PMCID: PMC13631501 -
JNJ-79032421, a Novel Membrane-Restricted Mesothelin-Targeting T Cell-Engaging Bispecific Antibody for the Treatment of Mesothelin-Positive Cancers.
- Smans K, Nesspor T, De Breucker S, van Heerde E, Valckx A, Van Slycken N, Sproesser K, Cypert BM, Packman K, Chu G, Fisher J, Mazzanti N, Petley T, Chan W, Del Rosario B, Liu T, Ember S, Shaffer PL, Clawson JS, Bauml JM, Moores S, Laquerre S, Gavine PR.
- Mol Cancer Ther. 2026 Oct 2;25(10):1585-1598. doi: 10.1158/1535-7163.MCT-25-0665.
- PMCID: PMC13631496
Smans K, et al.Mol Cancer Ther. 2026.PMCID: PMC13631496 -
Targeting Semaphorin 7a signaling in preclinical models of endocrine therapy-resistant breast cancer.
- Steinmetz RN, Wessells V, Fairchild H, Borges VF, Lyons TR.
- Mol Cancer Ther. Author manuscript. 2026 Apr 27:OF1-OF15. doi: 10.1158/1535-7163.MCT-25-0675. Online ahead of print.
- PMCID: PMC13556117
Steinmetz RN, et al.Mol Cancer Ther. Author manuscript. 2026.PMCID: PMC13556117 -
Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer.
- Ferrarini I, Louie A, Zhou L, El-Deiry WS.
- Mol Cancer Ther. 2026 Aug 4;25(8):1408. doi: 10.1158/1535-7163.MCT-26-0613.
- PMCID: PMC13548046
Ferrarini I, et al.Mol Cancer Ther. 2026.PMCID: PMC13548046 -
Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC.
- Gasendo JG, Chan S, Patel HV, Smith AE, Kessler L, Liu YA, Mitra A, Burrows F, Malik S.
- Mol Cancer Ther. 2026 Sep 2;25(9):1469-1479. doi: 10.1158/1535-7163.MCT-25-0449.
- PMCID: PMC13535317
Gasendo JG, et al.Mol Cancer Ther. 2026.PMCID: PMC13535317